A2B2 DOTA

A symmetrically functionalized DOTA derivative featuring a 2:2 ligand arrangement, optimized for complexing therapeutic radiometals like lutetium-177 and yttrium-90. Provides an ideal balance between metal chelation stability and bioconjugation efficiency, making it particularly suitable for targeted radionuclide therapy.

Additional Chelating Agents: A1B3 DOTA, A4 DOTA.

No products were found matching your selection.